Omnicell, Inc. (NASDAQ:OMCL) CFO Peter J. Kuipers sold 1,926 shares of Omnicell stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $51.69, for a total transaction of $99,554.94. Following the sale, the chief financial officer now owns 40,544 shares of the company’s stock, valued at approximately $2,095,719.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Omnicell, Inc. (NASDAQ OMCL) traded up $1.50 during midday trading on Thursday, reaching $50.45. 216,392 shares of the company were exchanged, compared to its average volume of 202,474. The firm has a market capitalization of $1,860.00, a PE ratio of -458.64, a P/E/G ratio of 4.00 and a beta of 0.71. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53. Omnicell, Inc. has a 52-week low of $32.10 and a 52-week high of $55.40.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.42. The firm had revenue of $186.78 million during the quarter, compared to analysts’ expectations of $192.45 million. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.40 earnings per share. analysts forecast that Omnicell, Inc. will post 0.12 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of OMCL. BlackRock Inc. lifted its stake in Omnicell by 2.3% in the second quarter. BlackRock Inc. now owns 4,589,119 shares of the company’s stock valued at $197,790,000 after buying an additional 101,776 shares in the last quarter. Vanguard Group Inc. lifted its stake in Omnicell by 3.7% in the second quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock valued at $83,105,000 after buying an additional 67,902 shares in the last quarter. Conestoga Capital Advisors LLC lifted its stake in Omnicell by 0.7% in the third quarter. Conestoga Capital Advisors LLC now owns 1,617,706 shares of the company’s stock valued at $82,584,000 after buying an additional 11,105 shares in the last quarter. Oak Ridge Investments LLC lifted its stake in Omnicell by 0.6% in the second quarter. Oak Ridge Investments LLC now owns 1,537,940 shares of the company’s stock valued at $66,285,000 after buying an additional 8,491 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Omnicell by 129.6% in the second quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock valued at $53,096,000 after buying an additional 695,334 shares in the last quarter. Hedge funds and other institutional investors own 99.61% of the company’s stock.
Several equities research analysts have recently commented on OMCL shares. Cantor Fitzgerald lifted their price target on shares of Omnicell to $58.00 and gave the stock an “overweight” rating in a research report on Friday, October 27th. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 1st. BidaskClub cut shares of Omnicell from a “hold” rating to a “sell” rating in a research report on Friday, December 22nd. Oppenheimer reiterated a “buy” rating and set a $55.00 price target on shares of Omnicell in a research report on Thursday, October 19th. Finally, Craig Hallum restated a “buy” rating and set a $62.00 price objective (up previously from $52.00) on shares of Omnicell in a report on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Omnicell presently has a consensus rating of “Hold” and a consensus target price of $55.14.
ILLEGAL ACTIVITY NOTICE: “Omnicell, Inc. (NASDAQ:OMCL) CFO Sells $99,554.94 in Stock” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/peter-j-kuipers-sells-1926-shares-of-omnicell-inc-omcl-stock.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.